Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

Immunogenicity assessment in non-clinical studies

(2012) Steven J Swanson et al.   CURRENT OPINION IN MICROBIOLOGY

Taking immunogenicity assessment of therapeutic proteins to the next level

(2011) I.C. Büttel et al.   BIOLOGICALS

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity of Therapeutic Proteins: The Use of Animal Models

(2011) Vera Brinks et al.   PHARMACEUTICAL RESEARCH

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

Preclinical development of monoclonal antibodies

(2010) Kathryn Chapman et al.   mAbs

Immunotoxicity of monoclonal antibodies

(2010) Jacques Descotes   mAbs

Have we overestimated the benefit of human(ized) antibodies?

(2010) Daniel R. Getts et al.   mAbs

A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering

(2010) Philippe Thullier et al.   mAbs

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

(2010) Frank R. Brennan et al.   mAbs

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

Safety evaluation of biological drugs: What are toxicology studies in primates telling us?

(2010) Paul Baldrick   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Antidrug Antibody Assay Validation: Industry Survey Results

(2009) Boris Gorovits   AAPS Journal

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

(2009) Rafael Ponce et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY